Tamera M.Weisser Ph.D. (Tammy)

Partner

(T) + 1.858.314.1181

Dr. Tamera (Tammy) Weisser is co-leader of Jones Day's global patent prosecution group, comprising more than 100 professionals worldwide. She has 20 years of experience in global patent portfolio development, management, and enforcement in biotechnology, particularly in the areas of biologics and diagnostics. For example, on behalf of NGM Biopharmaceuticals, Tammy coordinates the implementation of a global patent strategy concerning novel protein and antibody therapeutics in clinical trials for the treatment of diabetes, NASH (nonalcoholic steatohepatitis), and other metabolic disorders. On behalf of BioMarin, she established a worldwide patent portfolio for Palynziq®, an enzyme replacement therapy recently approved by the FDA for phenylketonuria treatment. She has developed IP strategies for dozens of antibody therapeutics for clients, including Celgene, Kyowa Hakko Kirin, and MedImmune (AstraZeneca). Commercial products for which Tammy has experience include EmboSpheres®, HepaSpheres®, Humira®, Kynamro®, Otezla®, Pomalyst®, Revlimid®, and Synagis®.

Her practice also includes performing patent validity and freedom-to-operate analyses and conducting due diligence of patent portfolios for clients, including potential investors, acquirers, and licensees. She has been involved in numerous oppositions before the European Patent Office as well as interferences.

In addition, Tammy has in-depth experience in inter partes review (IPR) proceedings. She successfully defended AbbVie in two IPRs brought by Amgen, five IPRs brought by Coherus, and another IPR brought by Sandoz in connection with patents related to formulations for AbbVie's antibody adalimumab, marketed as Humira®, in which the PTAB denied institution of each petition.

Tammy currently serves on the board of directors of BIOCOM, and she is consistently recognized as being a top attorney and for her leadership and contribution within the community.

Experience

  • NGM Biopharmaceuticals completes $107M IPOJones Day served as IP counsel in connection with the $107 million initial public offering of NGM Biopharmaceuticals, Inc. (NASDAQ: NGM).
  • Celgene acquires Juno Therapeutics for $9 billionOn behalf of Celgene Corporation, Jones Day conducted a large-scale intellectual property due diligence review and evaluation of matters related to its definitive merger agreement and acquisition of Juno Therapeutics for approximately $9 billion, including Juno’s technology related to CAR-T and TCR cellular immunotherapeutics for use in oncology and other indications.
  • AbbVie prevails in Sandoz IPR challenge of HUMIRA® formulation patentJones Day served as lead counsel and successfully defended AbbVie in connection with an inter partes review (IPR) petition filed by Sandoz, Inc. against U.S. Patent No. 8,802,100, which is related to formulations for AbbVie's antibody adalimumab, marketed as HUMIRA®.
  • Rain Therapeutics expands patent portfolio related to clinical stage cancer therapiesJones Day advised Rain Therapeutics Inc. in connection with global patent portfolio development related to a hypoxia-activated prodrug of a potent pan-HER inhibitor, Tarloxotinib (Tarlox), for the treatment of non-small cell lung cancer in patients with EGFR and HER exon 20 insertion mutations.
  • NGM establishes global patent portfolio related to novel protein therapiesJones Day represents NGM Biopharmaceuticals, Inc. in the establishment of a global patent portfolio related to novel protein therapies for the treatment of diabetes and other metabolic disorders.
  • AbbVie successfully defends HUMIRA formulation patent against four IPR petitions filed by CoherusJones Day is serving as lead counsel and successfully defended AbbVie in connection with four (4) separate inter partes review (IPR) petitions brought by Coherus Biosciences, Inc. against U.S. Patent No. 9,085,619, which is related to formulations for AbbVie's antibody adalimumab, marketed as HUMIRA®.
  • AbbVie defeats IPR petition filed by Coherus challenging Humira®Jones Day successfully defended AbbVie Inc. in connection with an IPR petition brought by Coherus Biosciences, Inc. against U.S. Patent No. 9,114,166, which is directed to formulations for AbbVie's antibody therapeutic Humira®.
  • AbbVie successfully defends patents related to HUMIRA® against IPR petitions filed by AmgenJones Day served as co-counsel in the successful defense of AbbVie Inc. in two IPRs brought by Amgen in connection with U.S. Patent Nos. 8,916,157 and 8,916,158 related to AbbVie's blockbuster antibody therapeutic, HUMIRA®.
  • Celgene develops global patent portfolio for agonistic anti-PD1 antibody therapeuticsJones Day represents Celgene Corporation in the establishment of a global patent portfolio related to agonistic anti-PD1 therapeutic antibodies.
  • AbbVie successfully faces off with Amgen in patent interference involving buffer-free antibody formulationsJones Day represented AbbVie, Inc. in a patent interference against Amgen, Inc. before the PTAB involving the parties' applications/patents generally related to buffer-free antibody formulations, including formulations to adalimumab, marketed as Humira®.
  • BioMarin establishes global patent portfolio for PAL technologyOn behalf of BioMarin Pharmaceutical, Inc., Jones Day assisted with global patent portfolio development and prosecution strategies regarding Prokaryotic Phenylalanine Ammonia-Lyase (PAL).
  • Celgene successfully defends REVLIMID® compound patent against Kyle Bass' IPR petitionJones Day represented Celgene Corporation in successfully defending an IPR petition filed by Coalition for Affordable Drugs VI LLC (CFAD) - a company formed by hedge fund manager Kyle Bass - against U.S. Patent No. 5,635,517, which is listed in the Orange Book for Celgene's REVLIMID® brand drug.
  • Genzyme (Sanofi) develops patent portfolio for antisense drug Kynamro®Jones Day represented Genzyme Corporation (Sanofi) in developing patent portfolios related to the apolipoprotein B-targeting antisense drug, Kynamro® (mipomersen), which was the first antisense drug to reach the market and used for the treatment of homozygous familial hypercholesterolemia.
  • Genomatica establishes global patent portfolios related to production of more sustainable versions of major chemicals, made from alternative feedstocksJones Day represents Genomatica in the development of a worldwide patent portfolio related to methods of producing high-volume basic and intermediate chemicals from alternative feedstocks, such as sugars and cellulosic biomass, using engineered microorganisms.
  • MedImmune establishes patent portfolio for Synagis® and Rezield®On behalf of MedImmune (now part of AstraZeneca), Jones Day managed the patent portfolio and prosecution strategy concerning certain RSV antibodies including palivizumab (Synagis®) and motavizumab (Rezield®).
  • Celgene establishes global patent portfolio for its brands REVLIMID®, POMALYST®, OTEZLA®, VIDAZA®, ABRAXANE® and ISTODAX®Jones Day assists Celgene Corporation in the establishment of its global patent portfolio related to lenalidomide (REVLIMID®), pomalidomide POMALYST®), apremilast (OTEZLA®), azacitidine (VIDAZA®), ABRAXANE® and romidepsin (ISTODAX®) for the treatments of cancer and immune, inflammatory conditions.
  • NGM develops global patent portfolio for beta-klotho antibodiesJones Day represents NGM Biopharmaceuticals, Inc. in the development of a global patent portfolio for antibodies to beta-klotho for the treatment of diabetes and other metabolic disorders.
  • Perlan establishes global patent portfolio for ICAM1 antibodiesJones Day represents Perlan Therapeutics, Inc. in connection with the global patent portfolio for ICAM1 antibodies for the treatment of rhinovirus and other respiratory infections.
  • Apsara establishes global patent portfolio for aquaporin-4 antibodiesJones Day represents Apsara Therapeutics, Inc. in the establishment of a global patent portfolio relating to aquaporin-4 (AQP4) antibodies for the treatment of neuromyelitis optica.
  • Isis Pharmaceuticals builds patent portfolio for certain clinical development compoundsOn behalf of Isis Pharmaceuticals, Inc., Jones Day assisted with patent prosecution strategy and portfolio development concerning some of its clinical development compounds.
  • Kirin Pharma Kabushiki Kaisha establishes patent portfolio for human LIGHT antibodiesJones Day represented Kirin Pharma Kabushiki Kaisha and Kirin Pharma USA, Inc. in the development of its patent portfolio and prosecution strategies related to human LIGHT antibodies.
  • Celgene files declaratory judgment action against CyclacelJones Day represents plaintiff Celgene Corporation in a declaratory judgment action for non-infringement and invalidity of four Cyclacel Pharmaceuticals, Inc. patents related to certain depsipeptides and uses thereof.
  • The Regents of the University of California establishes patent portfolio related to anti-CD22 antibodies for the treatment of B cell malignanciesJones Day assisted the Regents of the University of California in the development of a global patent portfolio related to uses of CD22 antibodies for the treatment of B cell malignancies, such as non-Hodgkin's lymphoma (NHL).
  • BioSphere Medical signs merger agreement with Merit Medical SystemsJones Day acted as IP counsel in advising BioSphere Medical, Inc. in connection with the execution of a definitive merger agreement with Merit Medical Systems, Inc., wherein Merit will acquire BioSphere in an all cash transaction valued at approximately $96 million.
  • GeoSynFuels strikes joint venture with Donald Danforth Plant Science Center, establishes Agrius BioForms, LLCJones Day represented GeoSynFuels in the formation of Agrius BioForms, LLC, a new joint venture established with the non-profit research center, the Donald Danforth Plant Science Center.
  • BioSphere purchases assets from RJ Medical, Inc.Jones Day advised BioSphere Medical, Inc. in its acquisitions of porous microsphere-related intellectual property and other assets from RJ Medical, Inc., which had previously acquired the same assets from Surgica Corporation.
  • Ambit Biosciences develops patent portfolio for small molecule kinase inhibitor programsJones Day represented Ambit Biosciences in the development of patent portfolios related to small molecule kinase inhibitor programs and phage-displayed protein assays.
  • BioSphere develops patent portfolio for Quadrasphere® / Hepasphere®Jones Day represented BioSphere Medical, inc. in the establishment and enforcement of its patent portfolio, including its Quadrasphere® / Hepasphere® and Embosphere® products.
  • Chembridge Research Labs develops patent portfolio for cell-free protein expression systemsJones Day represented Chembridge Research Laboratories in the development of patent portfolios related to cell-free protein expression systems.
  • Medical device manufacturer obtains strategic advice for multi-jurisdiction infringement litigationJones Day provided advice to a specialized U.S. medical device manufacturer on strategic options to enforce its patents in coordinated multi-jurisdiction infringement proceedings.
  • Apposite Capital invests in AmbrxJones Day advised Apposite Capital LLP in connection with its purchase of Series C Convertible Preferred Stock in a private placement by Ambrx, Inc., a biopharmaceutical company.
  • MacroGenics maintains patent portfolio for biologics, immunotherapeutics and cancer targetsJones Day managed the patent portfolio and prosecuted key patents on behalf of MacroGenics, Inc. related to biologics, immunotherapeutics and cancer targets, particularly with respect to antibodies and other molecules that target Fc receptors.
  • Monogram Biosciences maintains patent portfolio for medicine molecular diagnostics productsJones Day managed a patent portfolio for Monogram Biosciences (now LabCorp) related to individualized medicine molecular diagnostics products, including Phenosense™, GeneSeq™, and Replication Capacity™.
  • Isis Pharmaceuticals establishes patent portfolio for antisense oligonucleotides directed to IL-4R alphaJones Day assisted Isis Pharmaceuticals, Inc. in the development of a global patent portfolio related to antisense oligonucleotides and other oligomeric compounds that target interleukin-4 receptor alpha (IL-4Ra), as well as uses of those compounds for the prevention and treatment of various conditions associated with expression of IL-4Ra, such as pulmonary inflammation and airway hyperresponsiveness.
  • Additional Publications

    • 2001
      Th1 genetic adjuvants modulate immune responses in neonates, Vaccine. 19(13-14): 1764-1771
    • 2000
      DNA vaccines: Basic studies and applications, Advances in Virus Research, K. Maramorosch, F. Murphy, and A. Shatkin eds., Academic Press, New York, NY. 1-74
    • 2000
      DNA vaccines for influenza virus: Differential effects of maternal antibody on immune responses to hemagglutinin and nucleoprotein, J. Virol., 74(17)7787-7793
    • 2000
      Characterization of immune responses following neonatal DNA immunization, University of Massachusetts Medical School, Doctoral Thesis
    • 1999
      Studies on antibody responses following neonatal immunization with influenza hemagglutinin DNA or protein, Virology, 257(2):406-414
    • 1998
      Nucleic acid immunizations, in Current Protocols in Immunology, R. Coico ed., John Wiley and Sons, New York, NY. 2.14.1-2.14.19
    • 1996
      Influenza nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery, J. Virol, 70(9):6119-6125
    • 1995
      Gene gun-based nucleic acid immunization: Elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA, Vaccine, 13(15):1427-1430
    • 1994
      Accell® particle-mediated DNA immunization elicits humoral, cytotoxic, and protective immune responses, AIDS Res. Hum. Retroviruses, 10 Suppl. 2:S43-S45

    Speaking Engagements

    • October 5, 2016
      Professional Advancement: How to Make the Ask, Lawyers Club of San Diego
    • October 3, 2016
      Intellectual Property 101: Introduction to Patents and Technology Transfer in Industry and Academic Settings, Association for Women in Science
    • June 10, 2015
      The Scientist Magazine, Virtual Career Expo: Law & Regulatory Affairs, Webinar
    • March 21, 2015
      PhD STEM Career Symposium: Intellectual Property Law, Sanford Burnham Medical Research Institute
    • August 26, 2014
      University of San Diego School of Law Diversity Reception
    • May 19, 2014
      VIP Mentor Panel, 29th Annual California Women's Conference
    • March 1, 2014
      PhD STEM Career Symposium: Intellectual Property Law, Sanford Burnham Medical Research Institute
    • February 5, 2013
      Jones Day San Diego sponsors and hosts Lawyers' Club Work/Life Balance CLE program
    • February 4, 2013
      Jones Day San Francisco sponsors and hosts the Association for Women in Science (AWIS) "Strategy Sessions" seminar
    • October 4, 2012
      Jones Day Hosts California Client Development Event for Women
    • June 4, 2012
      AWIS Strategy Session, Professional Development Seminar
    • May 19, 2012
      Ph.D. Career Conference Panel Discussion, University of California San Diego
    • March 26, 2012
      IP Law Career Panel Discussion, University of San Diego School of Law
    • August 2, 2011
      Jones Day hosts Lawyers Club Work/Life Balance Lunch CLE Program in San Diego
    • August 1, 2011
      Jones Day hosts Association for Women in Science (AWIS) Strategy Session in San Diego
    • June 15, 2011
      Intellectual Property and Next Generation Sequencing, CLE presentation
    • June 7, 2011
      Jones Day hosts Lawyers Club Work/Life Balance Lunch CLE Program in San Diego
    • June 6, 2011
      Jones Day hosts Association for Women in Science (AWIS) Strategy Session in San Diego
    • May 14, 2011
      AWIS Women in Science and Technology Conference: Patent Law, Salk Institute for Biological Studies
    • May 2, 2011
      Introduction to Patent Law: Stem Cell Patents, California Polytechnic State University
    • May 2011
      Women in Science and Technology (WIST) conference
    • April 4, 2011
      Association for Women in Science (AWIS) bi-monthly Strategy Sessions
    • November 18, 2010
      Association for Women in Science (AWIS) Alternative Careers Panel Discussion: Patent Law
    • May 10, 2010
      Introduction to Patent Law: Patenting Stem Cells, California Polytechnic State University
    • March 11, 2010
      Introduction to Patent Law, San Diego State University
    • August 12, 2009
      Patents 101, Licensing and Exhaustion, CLE presentation
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.